Cancer Chemotherapy Reviews
Tuesday, October 19, 2021 
ISSN: 2462-4136
Subscribers area
Home Editorial Board Journal Contents Subscriptions Contact Us Authors Instructions
<<< back |

Role of Carboplatin in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

January-March 2015, Volume 02, Number 1
Raphael Brandão-Moreira, Jéssica Ribeiro-Gomes, Marcelo Rocha-Cruz and Antônio Carlos-Buzaid
Antonio Ermirio de Moraes Oncology Center, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil

Triple-negative breast cancer is the most aggressive subtype of breast tumors. After a better molecular understanding of breast cancer, the treatment of triple-negative tumors is challenging because there is no known potential therapeutic target. Recently, interesting data about the use of platinum has been published and has generated excitement, especially in patients harboring mutations in BRCA gene. In this paper, the use of platinum agents will be reviewed as a new therapeutic option for mutated BRCA and triple-negative breast cancer.

Key words:
Triple-negative breast cancer. Chemotherapy. Platinum. Neoadjuvant treatment.
[See pdf]
Temístocles, 315 – Colonia Polanco
Delegación Miguel Hidalgo
11560 Ciudad de México
© Permanyer | Made & Powered by PERMANYER | Privacy Policy - Legal notice